Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Leukemia 10Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Neoplasms 6Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Histologic Type 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1

Interventions

vandetanib 12cabozantinib 8selpercatinib 5Sorafenib 5Everolimus 5Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2pralsetinib 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Medullary × ponatinib × Clear all
NCT03838692 2021-10-13

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Columbia University

Phase 2 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡